Short-term Antiarrhythmic Drugs After Catheter Ablation for Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
The incidence of recurrent arrhythmia after catheter ablation (CA) for atrial fibrillation (AF) is unacceptable. Short-term antiarrhythmic drug (AAD) treatment following CA was presumed to be effective in reducing recurrent arrhythmia.



To fully evaluate the efficacy of short-term use of AADs following CA for AF in preventing recurrence of atrial tachyarrhythmias.



PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched up until May 1, 2016. We enrolled randomized controlled trials (RCTs) that evaluated the efficacy of short-term use of AADs following CA for AF in preventing early and/or late recurrence of atrial tachyarrhythmias. The statistical analyses were performed using Review Manager Version 5.3.



Six RCTs were included in this analysis, involving a total of 2764 patients. The frequency of early recurrence of atrial tachyarrhythmias was 39.5% in the AAD group (556 of 1407) and 47.2% (640 of 1357) in the control group. The pooled risk ratio of the AAD group to the control group was 0.78 (95% CI = 0.62-0.98). Regarding late recurrence of AF (LRAF), the incidence in the AAD group and the control group was 32.5% (420 of 1293) and 34.6% (450 of 1300), respectively. No significant difference was identified between the 2 groups (relative risk = 0.94, 95% CI = 0.85-1.05).



Short-term use of AADs following CA for AF reduced the incidence of early recurrent atrial tachyarrhythmias but did not prevent LRAF.
Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Buyun
B
Xu
Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Fang
F
Peng
Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Weiliang
W
Tang
Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Ye
Y
Du
Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China ghangyuan@hotmail.com.
Hangyuan
H
Guo
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D017115:Catheter Ablation / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013610:Tachycardia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents
antiarrhythmics; atrial fibrillation; catheter ablation; clinical trials; meta-analysis